DOCSLIB.ORG

Fosun International Ltd. Outlook Revised to Stable from Positive

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fosun International Ltd. Outlook Revised to Stable from Positive Fosun International Ltd. Outlook Revised To Stable From Positive On Higher Leverage; Ratings Affirmed • 29-Apr-2020 07:52 EDT View Analyst Contact Information • Table of Contents • A higher loan-to-value (LTV) ratio stemming from debt-funded acquisitions in 2019 and the current market volatility due to COVID-19 have reduced Fosun International Ltd.'s rating buffer. • In our view, the Chinese conglomerate's good bank funding channels and proven access to both onshore and offshore capital markets could temper the risk from its high short-term debt. • On April 29, 2020, S&P Global Ratings revised its rating outlook on Fosun to stable from positive. At the same time, we affirmed our 'BB' long-term issuer credit rating on Fosun and issue rating on the company's guaranteed senior unsecured debt. • The stable outlook reflects our expectation that Fosun will maintain good access to funding channels and make limited debt-funded acquisitions over the next 12 months. HONG KONG (S&P Global Ratings) April 29, 2020--S&P Global Ratings today took the rating actions listed above. Fosun's debt-funded investments in unlisted assets in 2019 have reduced its rating buffer. A higher LTV ratio and lower listed asset weighting have reduced the company's buffer. Its investments outpaced disposals by Chinese renminbi (RMB) 4.9 billion in 2019, with the gap funded by debt. This partially resulted in Fosun's LTV ratio rising to about 37% as of end-2019, from 35.5% as of end-2018. Moreover, the company's new investments were mostly in the primary market, which weakens its asset liquidity. The listed asset weighting decreased to about 42% as of end-2019, from 46% as of end-2018. A large and diversified portfolio enables Fosun to withstand volatilities. In our view, the company's highly diversified investment portfolio across several industries in different continents supports its flexibility in navigating market volatility and avoiding concentration risk in single markets. This provides a rating buffer. Fosun's portfolio value was about RMB238.7 billion as of end-2019 (after S&P Global Ratings' adjustment). We estimate the portfolio value was still above RMB230 billion as of April 24, 2020, because the appreciation in the value of Shanghai Fosun Pharmaceutical (Group) Co. Ltd. mostly offset the depreciation in the values of other listed assets, especially Fosun Tourism Group and Banco Comercial Português, S.A. As of April 24, Fosun's LTV was about 38%. Fosun's exposure to the consumer discretionary sector should be manageable. Shanghai Yuyuan Tourist Mart (Group) Co. Ltd. (8% of portfolio value), Fosun Tourism Group (2% of portfolio value), and Fosun Fashion Group (Cayman) Ltd. (1% of portfolio value) are Fosun's investees in the consumer discretionary sector (travel and high-end retail). These companies are particularly exposed to pressure from the COVID-19 fallout. However, these assets collectively account for 10%-15% of Fosun's portfolio value (as of April 24, 2020) and contributed 6%-7% of its dividend income in 2019. Moreover, Yuyuan and Fosun Tourism Group are both listed companies with good access to funding, and we see limited need for Fosun to infuse more capital. Diverse funding channels and proven access to markets should temper the risk of a high proportion of short-term debt. We see Fosun's high exposure to short-term debt as a risk, especially in the currently volatile capital market. As of end-2019, Fosun had 42% short-term and 58% long-term debt at the holding company level. That said, Fosun's good relationships with both domestic and overseas banks and its thus far good access to the capital market should mitigate the risks. In addition, the company's marketable securities, valued at RMB35.5 billion at end-2019, could provide some liquidity support. Even if Fosun does not liquidate the positions, the company could still pledge those shares for loans when needed. Weak operating cash flow poses risks to Fosun's LTV ratio, and its commitment to control debt is yet to be tested. Fosun's dividend income has been low relative to its portfolio size, with a dividend yield of less than 2%. This is because a large number of the company's investees are still in the growth stage and prefer reinvestments over distributing earnings. Therefore, we believe Fosun will raise additional debt of RMB6 billion to fund the operating cash flow deficit, which translates to a 2-3 percentage point increase in the LTV ratio. The company's financial policy is to maintain an LTV ratio of 35%-40% by managing its debt level. It could do this by using cash from asset disposals to fund investments or operating expenses. However, the commitment for, and execution of, this policy is yet to be tested because Fosun's target on investment return could limit its pace of divestment. The stable outlook reflects our expectation that Fosun will maintain good access to funding channels over the next 12 months. The stable outlook also reflects our expectation that the company will fund the majority of its investment with proceeds from asset disposals. In our view, at the current rating level, Fosun should be able to endure a short-term spike in the LTV ratio to marginally over 45% due to market volatility. We may lower the rating if Fosun's access to bank funding or capital markets weakens or the company fails to generate sufficient cash from asset disposals to fund its acquisitions. We may also lower the rating if Fosun's LTV ratio exceeds 45% for a prolonged period. We may raise the rating if Fosun improves its listed asset weighting to closer to 50% and maintains its LTV ratio sufficiently below 40%. An upgrade assumes that the company improves its capital structure with a longer weighted-average debt maturity. Related Criteria • Criteria | Corporates | General: Corporate Methodology: Ratios And Adjustments, April 1, 2019 • Criteria | Corporates | General: Reflecting Subordination Risk In Corporate Issue Ratings, March 28, 2018 • General Criteria: Guarantee Criteria, Oct. 21, 2016 • Criteria | Corporates | Industrials: Methodology: Investment Holding Companies, Dec. 1, 2015 • Criteria | Corporates | General: Methodology And Assumptions: Liquidity Descriptors For Global Corporate Issuers, Dec. 16, 2014 • Criteria | Corporates | General: Corporate Methodology, Nov. 19, 2013 • General Criteria: Country Risk Assessment Methodology And Assumptions, Nov. 19, 2013 • General Criteria: Methodology: Industry Risk, Nov. 19, 2013 • General Criteria: Methodology: Timeliness Of Payments: Grace Periods, Guarantees, And Use Of 'D' And 'SD' Ratings, Oct. 24, 2013 • General Criteria: Methodology: Management And Governance Credit Factors For Corporate Entities, Nov. 13, 2012 • General Criteria: Use Of CreditWatch And Outlooks, Sept. 14, 2009 Certain terms used in this report, particularly certain adjectives used to express our view on rating relevant factors, have specific meanings ascribed to them in our criteria, and should therefore be read in conjunction with such criteria. Please see Ratings Criteria at www.standardandpoors.com for further information. Complete ratings information is available to subscribers of RatingsDirect at www.capitaliq.com. All ratings affected by this rating action can be found on S&P Global Ratings' public website at www.standardandpoors.com. Use the Ratings search box located in the left column. European Endorsement Status Global-scale credit rating(s) have been endorsed in Europe in accordance with the relevant CRA regulations. Note: Endorsements for U.S. Public Finance global-scale credit ratings are done per request. To review the endorsement status by credit rating, visit the standardandpoors.com website and search for the rated entity. Primary Credit Analyst: Cher Chen, Hong Kong (852) 2533-3569; [email protected] Secondary Contact: Clifford Kurz, Hong Kong (852) 2533-3534; [email protected] No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of Standard & Poor’s Financial Services LLC or its affiliates (collectively, S&P). The Content shall not be used for any unlawful or unauthorized purposes. S&P and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an “as is” basis. S&P PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages. Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.
Load more

Recommended publications
  • For Personal Use Only Use Personal For
    13 November 2014 Norton Rose Fulbright Australia ABN 32 720 868 049 Level 15, RACV Tower 485 Bourke Street MELBOURNE VIC 3000 AUSTRALIA Tel +61 3 8686 6000 Company Announcements Fax +61 3 8686 6505 Australian Securities Exchange GPO Box 4592, Melbourne VIC 3001 Level 2 120 King Street DX 445 Melbourne MELBOURNE VIC 3000 nortonrosefulbright.com Direct line +61 3 8686 6710 Email [email protected] Our reference: 2813782 Dear Sir/Madam Takeover bid by Transcendent Resources Limited for Roc Oil Company Limited (ROC) – interests of substantial holder We act for Transcendent Resources Limited ( Fosun ) and its associated companies and controllers, which includes Fosun International Limited ( Fosun Parties ) in relation to Fosun’s off-market takeover bid for all of the ordinary shares in Roc Oil Company Limited ( ROC ). On behalf of the Fosun Parties and in accordance with section 671B of the Corporations Act 2001 (Cth), we enclose a notice of change of interests of substantial holder in respect of ROC ( Form 604 ). This notice will be provided to ROC today. Yours faithfully James Stewart Partner Norton Rose Fulbright Australia Encl. For personal use only APAC-#24924633-v1 Norton Rose Fulbright Australia is a law firm as defined in the Legal Profession Acts of the Australian states and territory in which it practises. Norton Rose Fulbright Australia, Norton Rose Fulbright LLP, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members of Norton Rose Fulbright Verein, a Swiss Verein.
    [Show full text]
  • August 28, 2012 FOLLI FOLLIE GROUP and FOSUN
    August 28, 2012 FOLLI FOLLIE GROUP AND FOSUN INTERNATIONAL: A GLOBAL PARTNERSHIP1 On May 4, 2011, Folli Follie, a Greek luxury jewelry designer and retail group, made a public announcement (Exhibit 1) that Fosun International, a large China-based holding company with a diverse portfolio of businesses, has agreed to acquire approximately 9.5% stake of Folli Follie Group at €84.58 million. Thus, Fosun, together with its affiliate, would acquire the newly issued stock through a private investment in public equity (PIPE) placement at €13.30 (compared to €12.75 the day before) per share and would jointly become one of Folli Follie Group’s largest strategic investors. At the same time, Folli Follie announced that the two groups intended to collaborate in their business development in China as well as in other parts of the world. The move would facilitate Folli Follie’s expansion in China, one of the world’s fastest growing markets for luxury goods. Folli Follie Group Dimitris Koutsolioutsos founded Folli Follie in 1982 together with his wife and business partner, Ketty Koutsolioutsos. It is headquartered in Athens, Greece. The company started its operations by establishing a shop in the centre of Athens. Folli Follie now designs, manufactures and distributes jewelery, watches and fashion accessories. The company started expanding in the Greek market through franchising, which allowed the company both to reduce the risk taken and to control the quality of the product offering. In 1995, Folli Follie opened its first overseas store in Japan. Due to the limited financial resources of the firm, the initial entry was achieved through the establishment of a joint venture with a well-known Japanese firm.2 The cooperation with a local firm provided Folli Follie with the necessary knowledge of the local market.
    [Show full text]
  • Centered Around Family, Deeply Rooted in China, Innovating a Global Happiness Ecosystem
    Tower S1, Bund Finance Center, 31st Floor，Beijing Fosun International Center， 600 Zhongshan No.2 Road(E) , Shanghai, China No.237 North Chaoyang Road，Chaoyang District, Beijing, China Tel: +86 21 2315 6666 Tel: +86 10 5915 2299 Fax: +86 21 6130 3288 Fax: +86 10 5915 2174 Post Code: 200010 Post Code: 100020 Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong 44th Floor, 28 Liberty (formerly One Chase Manhattan Plaza), Tel: +852 2509 3228 New York, NY, 10005, USA Fax: +852 2509 9028 Tel：＋1 646 490 9830 Centered around Family, Deeply Rooted in China, Innovating a Global Happiness Ecosystem Largo do Chiado 8, 107-0061 6F 3-5-12, 1249-125 Lisbon, Portugal Kita-Aoyama, Minato-ku, Tel：＋351 213 401 500 Tokyo, Japan Tel: +81 3 5775 7860 Fosun Group (April 2017) CONTENTS Fosun’s Business 02 Overview 10 Overview Fosun’s Fosun’s 22 Team 30 Pursuit F OSUN’S OVERVIEW Together, We Make a Difference – enriching the health, happiness and wealth of families around the world. ABOUT FOSUN Fosun was founded in 1992 in Shanghai. Fosun International Limited(00656.HK), was listed on the main board of the Hong Kong Stock Exchange on 16 July 2007. Taking roots in China with a global business presence, Fosun has principally engaged in three major business segments of health, happiness and wealth. Fosun brings together premium resources of talents, products and technologies, combines China’s growth momentum to innovate a C2M happiness ecosystem by in-depth industrial operation, integration and investment. Fosun proactively develops the businesses of health, happiness, and wealth to meet the needs of happy families lifestyles all over the world.
    [Show full text]
  • Fact Book 2013
    Fact Book 2013 Contents Shanghai Securities Market.......................................................1 Historical Review .........................................................................................................................................1 Securities Products ......................................................................................................................................1 2012 Market Review....................................................................5 Overview ....................................................................................................................................................5 Securities Issuance and Listing ......................................................................................................................5 Major Events in the Securities Market 2012 ....................................................................................................6 Market Highlights .........................................................................................................................................9 Transactions ................................................................................................................................................9 Stock Indices .............................................................................................................................................10 Ratios .......................................................................................................................................................10
    [Show full text]
  • 17 November 2014 Company Announcements Australian
    17 November 2014 Norton Rose Fulbright Australia ABN 32 720 868 049 Level 15, RACV Tower 485 Bourke Street MELBOURNE VIC 3000 AUSTRALIA Tel +61 3 8686 6000 Company Announcements Fax +61 3 8686 6505 Australian Securities Exchange GPO Box 4592, Melbourne VIC 3001 Level 2 120 King Street DX 445 Melbourne MELBOURNE VIC 3000 nortonrosefulbright.com Direct line +61 3 8686 6710 Email [email protected] Our reference: 2813782 Dear Sir/Madam Takeover bid by Transcendent Resources Limited for Roc Oil Company Limited (ROC) – interests of substantial holder We act for Transcendent Resources Limited ( Fosun ) and its associated companies and controllers, which includes Fosun International Limited ( Fosun Parties ) in relation to Fosun’s off-market takeover bid for all of the ordinary shares in Roc Oil Company Limited ( ROC ), which closed on 14 November 2014. On behalf of the Fosun Parties and in accordance with section 671B of the Corporations Act 2001 (Cth), we enclose a notice of change of interests of substantial holder in respect of ROC ( Form 604 ). The notice will be provided to ROC today. Yours faithfully James Stewart Partner Norton Rose Fulbright Australia Encl. APAC-#24954514-v1 Norton Rose Fulbright Australia is a law firm as defined in the Legal Profession Acts of the Australian states and territory in which it practises. Norton Rose Fulbright Australia, Norton Rose Fulbright LLP, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members of Norton Rose Fulbright Verein, a Swiss Verein.
    [Show full text]
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
    THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser. If you have sold or transferred all your shares in Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*, you should at once hand this circular, together with the enclosed form of proxy, to the purchaser(s) or transferee(s) or to the bank, stockbroker or other agents through whom the sale or transfer was effected for transmission to the purchaser(s) or transferee(s). Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular. 上海復星醫藥（集團）股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (a joint stock limited company incorporated in the People’s Republic of China with limited liability) (Stock Code: 02196) CONNECTED TRANSACTIONS ENTERING INTO EQUITY TRANSFER AND LOAN ASSIGNMENT CONTRACT AND NOTICE OF EGM A letter from the Board is set out on pages 7 to 16 of this circular. The notice convening the EGM to be held at 1:30 p.m. on Thursday, 27 May 2021 at Shanghai Film Art Center, No. 160 Xinhua Road, Shanghai, the PRC is set out on pages EGM-1 to EGM-2 of this circular.
    [Show full text]
  • Annual Report 2018
    ANNUAL REPORT 2018 (Incorporated in Hong Kong with limited liability) (Stock Code : 00656) 极 智 INNOVATION FOR EXCELLENCE Profit Attributable to Owners of the Parent RMB13,406.4 million Innovation for Excellence Product Competitiveness | Brand Strength | Industrial Group 2018 was a year full of uncertainties and challenges. Yet, thanks to our resilient business model of “Industry Operations + Industrial Investment” with “Glocalization” that Fosun has adhered to throughout these years, the Group still managed to deliver steady growth for its full-year financial results. This year, Fosun emphasises on three keywords – “Product Competitiveness, Brand Strength and Industrial Group”. We have learnt and believed that “Going Back to the Basics” or “Going Back to the Nature of Business” can undoubtedly strengthen our foundation. More fundamentally, we believe only if we can focus on enhancing our product competitiveness and brand influence, a strong industrial group and a global ecosystem can be established. With an increasing number of mature industrial groups that Fosun has helped tap into the capital markets, the Group accomplished its business model of “1 Ecosystem + N Industrial Groups”. This has also enabled the Group to have a more clear business structure, unlocking growth momentum and value. Going forward, Fosun’s business will continue to centre on the family, remain focused on enhancing product competitiveness, building brand strength while further promoting the empowerment and synergies within industrial groups. With our roots in China,
    [Show full text]
  • 股 份 有 限 公 司 Shanghai Fosun Pharmaceutical
    Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (a joint stock limited company incorporated in the People’s Republic of China with limited liability) (Stock Code: 02196) CONNECTED TRANSACTION ENTERING INTO THE PURCHASE AGREEMENT REGARDING THE ACQUISITION OF INTEREST IN A SUBSIDIARY THE PURCHASE AGREEMENT The Board announces that, on 9 June 2021, the Buyer, a subsidiary of the Company, and the Seller entered into the Purchase Agreement, pursuant to which the Seller agreed to sell and the Buyer agreed to purchase the Sale Interest in NOVA held by the Seller at the purchase price of US$7.32 million. Upon completion of the transaction under the Purchase Agreement, NOVA will become a wholly-owned subsidiary of the Company. HONG KONG LISTING RULES IMPLICATIONS As the Seller is a subsidiary of Fosun International, the controlling shareholder of the Company, the Seller constitutes an associate of the Fosun International and a connected person of the Company pursuant to Chapter 14A of the Hong Kong Listing Rules. Therefore, the transaction contemplated under the Purchase Agreement constitutes a connected transaction of the Company under Chapter 14A of the Hong Kong Listing Rules.
    [Show full text]
  • Interim REPORT 2020
    INTERIM REPORT 2020 (Incorporated in Hong Kong with limited liability) (Stock Code : 00656) INTER I M RE PO RT 2020 FOSUN INTERNATIONAL An Innovation-Driven Consumer Group “Resilience & Strength” In 2019, Fosun formally defined the new positioning of “innovation-driven consumer group” and put forward the “Focus” strategy for the first time in early 2020. It indicated that Fosun has completed the preliminary industrial and regional expansion deployment. The next strategic focus will be strengthening Fosun’s existing industries and regional operations, and continue to enhance the competitiveness and operational efficiency of its industry operations. In 2020, the world has been severely hit by the COVID-19 epidemic. Fosun’s global businesses encountered challenges due to the epidemic in the first half of the year. However, its financial position remained solid and its liquidity stayed strong. If Fosun is to sum up its performance for the first half of 2020 in one word, that word will be “resilience”. Fosun’s diversified business mix, global asset allocation and “Industry Operations + Industrial Investment” model for development have enabled Fosun to effectively hedge against market risks and seize opportunities in times of crises and changes. At the same time, Fosun’s industry operations have also shown great resilience by virtue of its profound experience in their industries and long-term investment in innovation. More importantly, the epidemic has brought a new organizational evolution to Fosun. Upon the outbreak of the epidemic, we have promptly activated our wartime mechanism for fighting against the disease. The move has strengthened our organizational and execution capabilities. Meanwhile, we have been able to ensure the safety of both our customers and employees while seeking opportunities in times of crises.
    [Show full text]
  • Fosun and Club Med
    2016 Northeast Asia International Conference for Economic Development (NICE) in Niigata D-ZHOU A “New Normal” in China’s Economy and Corporate Strategies Li ZHOU 周立 Assistant Dean 助理院长 CKGSB 长江商学院 Agenda A “New Normal” in China’s Economy A “New Normal” in Chinese Companies Overview The Fosun Case CKGSB-A Global Business School for Global Leaders Conclusions 2 ©ERINA 2016 Northeast Asia International Conference for Economic Development (NICE) in Niigata D-ZHOU A New Normal in China’s Economy New Normal in China’s Economy Old New Economic Growth 10% 6.5% Role in the Global Made in China Sold in China Economy (Factory) (Market) Capital Flows To China From China High Growth Sectors Industrial Services Higher Growth Cities Coastal Inland 4 ©ERINA 2016 Northeast Asia International Conference for Economic Development (NICE) in Niigata D-ZHOU Firms with Severe Excess Capacity Source: “China’s Industrial Economy Report, 2015 Q3 Survey” led by Prof. Gan Jie, Center on Finance and Economic Growth, CKGSB 5 Challenges of China’s Industrial Firms Source: “China’s Industrial Economy Report, 2015 Q3 Survey” led by Prof. Gan Jie, Center on Finance and Economic Growth, CKGSB 6 ©ERINA 2016 Northeast Asia International Conference for Economic Development (NICE) in Niigata D-ZHOU Services as a Part of GDP 16 60 14.2 14 Services, etc., value added 50 12.7 (% of GDP) 12 10.6 Industry, value added (% of GDP) 40 9.6 9.5 10 9.2 8.4 7.8 7.7 8 7.3 30 6 20 3.9 4 Agriculture, value added 10 2 (% of GDP) 0 0 1990 2000 2006 2007 2008 2009 2010 2011 2012 2013 2014
    [Show full text]
  • China Jewelry Industry Report, 2013-2016
    China Jewelry Industry Report, 2013-2016 Jun. 2014 STUDY GOAL AND OBJECTIVES METHODOLOGY This report provides the industry executives with strategically significant Both primary and secondary research methodologies were used competitor information, analysis, insight and projection on the in preparing this study. Initially, a comprehensive and exhaustive competitive pattern and key companies in the industry, crucial to the search of the literature on this industry was conducted. These development and implementation of effective business, marketing and sources included related books and journals, trade literature, R&D programs. marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. REPORT OBJECTIVES Subsequently, telephone interviews or email correspondence To establish a comprehensive, factual, annually updated and cost- was conducted with marketing executives etc. Other sources effective information base on market size, competition patterns, included related magazines, academics, and consulting market segments, goals and strategies of the leading players in the companies. market, reviews and forecasts. To assist potential market entrants in evaluating prospective INFORMATION SOURCES acquisition and joint venture candidates. The primary information sources include Company Reports, To complement the organizations’ internal competitor information and National Bureau of Statistics of China etc. gathering efforts with strategic analysis, data interpretation and insight.
    [Show full text]
  • Interim Report
    Contents 2009 Interim Report Financial Summary 2 Business Overview 3 Chairman’s Statement 5 Financial Review 9 Interim Condensed Consolidated Income Statement 16 Interim Condensed Consolidated Statement of Comprehensive Income 17 Interim Condensed Consolidated Statement of Financial Position 18 Interim Condensed Consolidated Statement of Changes in Equity 20 Interim Condensed Consolidated Statement of Cash Flows 22 Notes to Interim Condensed Consolidated Financial Statements 23 Statutory Disclosures 47 Corporate Information 51 Glossary 52 Fosun International Limited 1 Financial Summary 2009 Interim Report For the six months ended 30 June In RMB million 2009 2008 Revenue 15,972.0* 20,782.8* Revenue of each segment Pharmaceuticals 1,740.2 1,880.5 Property development 2,003.6 1,033.1 Steel 11,674.3 16,604.2 Mining 889.2 1,848.8 Profit attributable to equity holders of the parent 1,316.3 1,921.4 Contribution of each segment to the profit attributable to equity holders of the parent Pharmaceuticals 159.4 196.1 Property development 186.8 23.2 Steel 769.9 1,086.1 Mining 101.9 880.9 Retail, services and others (including unallocated expenses) 98.3 (264.9) Earnings per share (in RMB) 0.20 0.30 * Intersegment sales amounting to RMB335.3 million and RMB583.8 million have been eliminated in the consolidated revenue for the six months ended 30 June 2009 and the six months ended 30 June 2008, respectively. Fosun International Limited 2 Business Overview 2009 Interim Report With operations based in China, the Group has an excellent insight into the domestic market.
    [Show full text]